• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.Janus激酶1在弥漫性大B细胞淋巴瘤中的表观遗传基因调控
Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7260-E7267. doi: 10.1073/pnas.1610970113. Epub 2016 Oct 31.
2
Nuclear Import of JAK1 Is Mediated by a Classical NLS and Is Required for Survival of Diffuse Large B-cell Lymphoma.JAK1的核输入由经典核定位信号介导,是弥漫性大B细胞淋巴瘤存活所必需的。
Mol Cancer Res. 2017 Mar;15(3):348-357. doi: 10.1158/1541-7786.MCR-16-0344. Epub 2016 Dec 28.
3
Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.通过信号转导和转录激活因子3与核因子-κB通路在弥漫性大B细胞淋巴瘤亚型中的协同信号传导
Blood. 2008 Apr 1;111(7):3701-13. doi: 10.1182/blood-2007-09-111948. Epub 2007 Dec 26.
4
Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.细胞因子受体信号对于 ALK-间变性大细胞淋巴瘤的存活是必需的,即使存在 JAK1/STAT3 突变也是如此。
Proc Natl Acad Sci U S A. 2017 Apr 11;114(15):3975-3980. doi: 10.1073/pnas.1700682114. Epub 2017 Mar 29.
5
Oncogenically active MYD88 mutations in human lymphoma.人类淋巴瘤中致癌性激活的 MYD88 突变。
Nature. 2011 Feb 3;470(7332):115-9. doi: 10.1038/nature09671. Epub 2010 Dec 22.
6
Gene regulation and suppression of type I interferon signaling by STAT3 in diffuse large B cell lymphoma.STAT3 在弥漫性大 B 细胞淋巴瘤中对 I 型干扰素信号的基因调控和抑制作用。
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):E498-E505. doi: 10.1073/pnas.1715118115. Epub 2018 Jan 2.
7
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.HCK 是一种由突变型 MYD88 反式激活的生存决定因子,也是伊布替尼的直接作用靶点。
Blood. 2016 Jun 23;127(25):3237-52. doi: 10.1182/blood-2016-01-695098. Epub 2016 May 3.
8
USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma.USP7 通过稳定弥漫性大 B 细胞淋巴瘤中的 MLL2 和 WDR5 来维持活跃的表观遗传程序。
Cell Biochem Funct. 2022 Jun;40(4):379-390. doi: 10.1002/cbf.3702. Epub 2022 Apr 12.
9
Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.Fbw7通过靶向Stat3进行泛素化和降解来调节活化B细胞样弥漫性大B细胞淋巴瘤中的细胞凋亡。
J Exp Clin Cancer Res. 2017 Jan 10;36(1):10. doi: 10.1186/s13046-016-0476-y.
10
MiR-155 regulates lymphoma cell proliferation and apoptosis through targeting SOCS3/JAK-STAT3 signaling pathway.miR-155 通过靶向 SOCS3/JAK-STAT3 信号通路调节淋巴瘤细胞增殖和凋亡。
Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5153-5159. doi: 10.26355/eurrev_201711_13832.

引用本文的文献

1
Morphological, phenotypical and molecular characterization of canine lymphomas with dual T- and B-cell markers expression.具有双T细胞和B细胞标志物表达的犬淋巴瘤的形态学、表型和分子特征
Front Vet Sci. 2025 Apr 22;12:1578425. doi: 10.3389/fvets.2025.1578425. eCollection 2025.
2
PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial.PI3Kδ抑制剂林普利塞联合吉西他滨和奥沙利铂治疗复发或难治性弥漫性大B细胞淋巴瘤:一项多中心、单臂I b/II期试验
Cancer Cell Int. 2025 Feb 8;25(1):39. doi: 10.1186/s12935-025-03669-2.
3
TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma.肿瘤坏死因子受体相关因子3功能缺失揭示非经典核因子κB信号通路可作为弥漫性大B细胞淋巴瘤的治疗靶点。
Proc Natl Acad Sci U S A. 2024 Apr 30;121(18):e2320421121. doi: 10.1073/pnas.2320421121. Epub 2024 Apr 25.
4
Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma.靶向 DNMT3A 介导的氧化磷酸化克服套细胞淋巴瘤中伊布替尼耐药。
Cell Rep Med. 2024 Apr 16;5(4):101484. doi: 10.1016/j.xcrm.2024.101484. Epub 2024 Mar 29.
5
FERM domain-containing proteins are active components of the cell nucleus.FERM 结构域蛋白是细胞核的活性成分。
Life Sci Alliance. 2024 Jan 31;7(4). doi: 10.26508/lsa.202302489. Print 2024 Apr.
6
Analysis of autophagy in DLBCL reveals subtype-specific differences and the preferential targeting of ULK1 inhibition in GCB-DLBCL provides a rationale as a new therapeutic approach.弥漫性大B细胞淋巴瘤(DLBCL)中自噬的分析揭示了亚型特异性差异,并且在生发中心B细胞样弥漫性大B细胞淋巴瘤(GCB-DLBCL)中对ULK1抑制的优先靶向提供了一种作为新治疗方法的理论依据。
Leukemia. 2024 Feb;38(2):424-429. doi: 10.1038/s41375-024-02147-4. Epub 2024 Jan 23.
7
Molecular Characterization and Genetic Subclassification Comparison of Diffuse Large B-Cell Lymphoma: Real-Life Experience with 74 Cases.弥漫性大 B 细胞淋巴瘤的分子特征和遗传亚型比较:74 例真实世界经验。
Pathobiology. 2024;91(4):245-253. doi: 10.1159/000535938. Epub 2023 Dec 21.
8
Computational simulation of JAK/STAT signaling in somatic versus germline stem cells.体细胞与生殖细胞干细胞中 JAK/STAT 信号转导的计算模拟。
Dev Dyn. 2024 Jul;253(7):648-658. doi: 10.1002/dvdy.684. Epub 2023 Dec 21.
9
JAK-STAT signaling in inflammation and stress-related diseases: implications for therapeutic interventions.JAK-STAT信号通路在炎症和应激相关疾病中的作用:对治疗干预的启示
Mol Biomed. 2023 Nov 8;4(1):40. doi: 10.1186/s43556-023-00151-1.
10
EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma.EGR1 介导的代谢重编程向氧化磷酸化有助于 B 细胞淋巴瘤对伊布替尼的耐药性。
Blood. 2023 Nov 30;142(22):1879-1894. doi: 10.1182/blood.2023020142.

本文引用的文献

1
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.CARMA1和MyD88依赖的Jun/ATF型AP-1复合物激活是ABC弥漫性大B细胞淋巴瘤的一个标志。
Blood. 2016 Apr 7;127(14):1780-9. doi: 10.1182/blood-2015-07-655647. Epub 2016 Jan 8.
2
Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases.I/II 型细胞因子、Janus激酶与自身免疫性疾病的治疗新策略
Nat Rev Rheumatol. 2016 Jan;12(1):25-36. doi: 10.1038/nrrheum.2015.167. Epub 2015 Dec 3.
3
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.在弥漫性大B细胞淋巴瘤中使用依鲁替尼靶向B细胞受体信号传导
Nat Med. 2015 Aug;21(8):922-6. doi: 10.1038/nm.3884. Epub 2015 Jul 20.
4
Global target mRNA specification and regulation by the RNA-binding protein ZFP36.RNA结合蛋白ZFP36对全局靶mRNA的特异性识别与调控
Genome Biol. 2014 Jan 8;15(1):R12. doi: 10.1186/gb-2014-15-1-r12.
5
STAT3 targets suggest mechanisms of aggressive tumorigenesis in diffuse large B-cell lymphoma.STAT3 靶点提示弥漫性大 B 细胞淋巴瘤侵袭性肿瘤发生的机制。
G3 (Bethesda). 2013 Dec 9;3(12):2173-85. doi: 10.1534/g3.113.007674.
6
Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma.靶向鞘氨醇激酶诱导与 KSHV 相关的原发性渗出性淋巴瘤细胞凋亡和肿瘤消退。
Mol Cancer Ther. 2014 Jan;13(1):154-64. doi: 10.1158/1535-7163.MCT-13-0466. Epub 2013 Oct 18.
7
JAKs and STATs in immunity, immunodeficiency, and cancer.免疫、免疫缺陷和癌症中的JAKs与STATs
N Engl J Med. 2013 Jan 10;368(2):161-70. doi: 10.1056/NEJMra1202117.
8
Cancer epigenetics: from mechanism to therapy.癌症表观遗传学:从机制到治疗。
Cell. 2012 Jul 6;150(1):12-27. doi: 10.1016/j.cell.2012.06.013.
9
Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma.利用合成致死性治疗 ABC 弥漫性大 B 细胞淋巴瘤。
Cancer Cell. 2012 Jun 12;21(6):723-37. doi: 10.1016/j.ccr.2012.05.024.
10
Janus kinase deregulation in leukemia and lymphoma.白血病和淋巴瘤中的 Janus 激酶失调。
Immunity. 2012 Apr 20;36(4):529-41. doi: 10.1016/j.immuni.2012.03.017.

Janus激酶1在弥漫性大B细胞淋巴瘤中的表观遗传基因调控

Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.

作者信息

Rui Lixin, Drennan Amanda C, Ceribelli Michele, Zhu Fen, Wright George W, Huang Da Wei, Xiao Wenming, Li Yangguang, Grindle Kreg M, Lu Li, Hodson Daniel J, Shaffer Arthur L, Zhao Hong, Xu Weihong, Yang Yandan, Staudt Louis M

机构信息

Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892;

Department of Medicine, School of Medicine and Public Health, University of Wisconsin, Madison, WI 53705.

出版信息

Proc Natl Acad Sci U S A. 2016 Nov 15;113(46):E7260-E7267. doi: 10.1073/pnas.1610970113. Epub 2016 Oct 31.

DOI:10.1073/pnas.1610970113
PMID:27799566
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5135360/
Abstract

Janus kinases (JAKs) classically signal by activating STAT transcription factors but can also regulate gene expression by epigenetically phosphorylating histone H3 on tyrosine 41 (H3Y41-P). In diffuse large B-cell lymphomas (DLBCLs), JAK signaling is a feature of the activated B-cell (ABC) subtype and is triggered by autocrine production of IL-6 and IL-10. Whether this signaling involves STAT activation, epigenetic modification of chromatin, or both mechanisms is unknown. Here we use genetic and pharmacological inhibition to show that JAK1 signaling sustains the survival of ABC DLBCL cells. Whereas STAT3 contributed to the survival of ABC DLBCL cell lines, forced STAT3 activity could not protect these cells from death following JAK1 inhibition, suggesting epigenetic JAK1 action. JAK1 regulated the expression of nearly 3,000 genes in ABC DLBCL cells, and the chromatin surrounding many of these genes was modified by H3Y41-P marks that were diminished by JAK1 inhibition. These JAK1 epigenetic target genes encode important regulators of ABC DLBCL proliferation and survival, including IRF4, MYD88, and MYC. A small molecule JAK1 inhibitor cooperated with the BTK inhibitor ibrutinib in reducing IRF4 levels and acted synergistically to kill ABC DLBCL cells, suggesting that this combination should be evaluated in clinical trials.

摘要

Janus激酶(JAKs)传统上通过激活STAT转录因子来传递信号,但也可通过对酪氨酸41位点的组蛋白H3(H3Y41-P)进行表观遗传磷酸化来调节基因表达。在弥漫性大B细胞淋巴瘤(DLBCLs)中,JAK信号是活化B细胞(ABC)亚型的一个特征,由IL-6和IL-10的自分泌产生所触发。这种信号传导是涉及STAT激活、染色质的表观遗传修饰,还是这两种机制尚不清楚。在这里,我们使用基因和药物抑制来表明JAK1信号维持ABC DLBCL细胞的存活。虽然STAT3有助于ABC DLBCL细胞系的存活,但强制激活STAT3并不能保护这些细胞在JAK1抑制后免于死亡,这表明JAK1存在表观遗传作用。JAK1调节ABC DLBCL细胞中近3000个基因的表达,许多这些基因周围的染色质被H3Y41-P标记修饰,而这些标记在JAK1抑制后减少。这些JAK1表观遗传靶基因编码ABC DLBCL增殖和存活的重要调节因子,包括IRF4、MYD88和MYC。一种小分子JAK1抑制剂与BTK抑制剂依鲁替尼协同作用降低IRF4水平,并协同杀死ABC DLBCL细胞,这表明这种联合疗法应在临床试验中进行评估。